BACKGROUND: Tuberculosis (TB) incidence in Cameroon is high with 32% of adult TB patients, all forms, co-infected with HIV. The Nylon District Hospital in Douala runs a centre for the diagnosis and treatment of TB since 2001 and a pioneer Human Immunodeficiency Virus (HIV)/Acquired Immune deficiency Syndrome (AIDS) management programme at district level since 2000. OBJECTIVE: To determine the prevalence of HIV infection in TB patients from 2003 to 2006 and to analyse the pattern of TB/HIV co-infection rate over time. DESIGN: A retrospective study. SETTING: Nylon District Hospital, Douala, Cameroon. RESULTS: The prevalence of HIV infection in TB patients was 51.6%. This was greater for patients living out of the Nylon Health District (P = 0.001). Smear positive pulmonary tuberculosis (SPPT) was the most frequent (65%) form of TB diagnosed but extrapulmonary tuberculosis (EPT) and smear negative pulmonary tuberculosis (SNPT) were more frequently associated with HIV co-infection (80% and 68.6% respectively). While men and women presented equally with TB, women (61.4%) were significantly (P < 0.0001) more TB/HIV co-infected than men (42%). The co-infection rate was highest among individuals aged 25-44 years (61.4%) and least among the 0-24 years age group (22.5%). The increase in TB/HIV co-infection rate is monotonic over time with a stronger trend among females aged 25-44 years (P = 0.037) and above 45 years (P = 0.001). CONCLUSION: The NDH selectively attracted HIV positive patients to adhere to their HIV programme. The creation of HIV/AIDS treatment units in institutions providing TB diagnosis and treatment services will reduce the movement of TB/HIV co-infected patients across provinces and health districts as well as enhancing TB/HIV co-infection diagnosis and notification.
BACKGROUND:Tuberculosis (TB) incidence in Cameroon is high with 32% of adult TB patients, all forms, co-infected with HIV. The Nylon District Hospital in Douala runs a centre for the diagnosis and treatment of TB since 2001 and a pioneer Human Immunodeficiency Virus (HIV)/Acquired Immune deficiency Syndrome (AIDS) management programme at district level since 2000. OBJECTIVE: To determine the prevalence of HIV infection in TB patients from 2003 to 2006 and to analyse the pattern of TB/HIV co-infection rate over time. DESIGN: A retrospective study. SETTING: Nylon District Hospital, Douala, Cameroon. RESULTS: The prevalence of HIV infection in TB patients was 51.6%. This was greater for patients living out of the Nylon Health District (P = 0.001). Smear positive pulmonary tuberculosis (SPPT) was the most frequent (65%) form of TB diagnosed but extrapulmonary tuberculosis (EPT) and smear negative pulmonary tuberculosis (SNPT) were more frequently associated with HIV co-infection (80% and 68.6% respectively). While men and women presented equally with TB, women (61.4%) were significantly (P < 0.0001) more TB/HIV co-infected than men (42%). The co-infection rate was highest among individuals aged 25-44 years (61.4%) and least among the 0-24 years age group (22.5%). The increase in TB/HIV co-infection rate is monotonic over time with a stronger trend among females aged 25-44 years (P = 0.037) and above 45 years (P = 0.001). CONCLUSION: The NDH selectively attracted HIV positive patients to adhere to their HIV programme. The creation of HIV/AIDS treatment units in institutions providing TB diagnosis and treatment services will reduce the movement of TB/HIV co-infectedpatients across provinces and health districts as well as enhancing TB/HIV co-infection diagnosis and notification.
Authors: Henry Namme Luma; Benjamin Clet Nguenkam Tchaleu; Bertrand Hugo Mbatchou Ngahane; Elvis Temfack; Marie Solange Doualla; Marie Patrice Halle; Henry Achu Joko; Sinata Koulla-Shiro Journal: AIDS Res Ther Date: 2013-06-11 Impact factor: 2.250
Authors: Dickson Shey Nsagha; Benjamin Thumamo Pokam; Jules Clement Nguedia Assob; Anna Longdoh Njunda; Odette Dzemo Kibu; Elvis Asangbeng Tanue; Charlotte Wenze Ayima; Patrick Elroy Weledji Journal: BMC Public Health Date: 2015-10-09 Impact factor: 3.295